A Retrospective Real-World Study on the Efficacy and Safety of Anlotinib Hydrochloride Combined With Immunotherapy Maintenance Therapy Following Standard Chemoimmunotherapy for ES-SCLC (ALTER-L059)
Not yet recruitingOBSERVATIONAL
Enrollment
100
Participants
Timeline
Start Date
August 1, 2025
Primary Completion Date
December 31, 2025
Study Completion Date
December 31, 2025
Conditions
Small Cell Lung Cancer Extensive Stage
All Listed Sponsors
lead
Yong Fang
OTHER
NCT06982287 - A Retrospective Real-World Study on the Efficacy and Safety of Anlotinib Hydrochloride Combined With Immunotherapy Maintenance Therapy Following Standard Chemoimmunotherapy for ES-SCLC (ALTER-L059) | Biotech Hunter | Biotech Hunter